Jennifer Camas, MD
Pediatrics · Brownsville, KYNPI 1902828114
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 445 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 26.2% of the total. Among pediatrics clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 445 payments — averaging $13.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$831
- Novartis$596
- Axsome Therapeutics, Inc.$388
- Novo Nordisk$344
- AstraZeneca$265
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,78899%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 167 | $1,528 |
| Lilly USA, LLC | 58 | $831 |
| Novartis | 37 | $596 |
| Axsome Therapeutics, Inc. | 24 | $388 |
| Novo Nordisk | 27 | $344 |
| AstraZeneca | 15 | $265 |
| Corcept Therapeutics | 16 | $242 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $168 |
| Lundbeck LLC | 9 | $162 |
| Regeneron Healthcare Solutions, Inc. | 8 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $131 |
| Bayer | 6 | $105 |
| GSK | 6 | $97 |
| Amgen | 6 | $91 |
| Amarin Pharma, Inc. | 5 | $74 |
| Pfizer | 4 | $62 |
| Corium, LLC | 4 | $58 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Medtronic | 4 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Tactile Systems Technology Inc | 2 | $43 |
| Dexcom, Inc. | 2 | $32 |
| Ironshore Pharmaceuticals Inc. | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Tonix Medicines, Inc. | 1 | $23 |
| Johnson & Johnson | 2 | $23 |
| Sanofi | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Cequr Corporation | 1 | $18 |
| Verona Pharma, Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $10 |
How this compares
$5,823 in reported general payments places this provider in the 95th percentile of 777 pediatrics providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 135 | $144,068 |
| EntrestoSacubitril/Valsartan | 102 | $104,858 |
| Humira(Cf) PenAdalimumab | 11 | $75,863 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $72,749 |
| FarxigaDapagliflozin Propanediol | 73 | $66,805 |
| Repatha SyringeEvolocumab | 97 | $65,909 |
| OzempicSemaglutide | 37 | $52,000 |
| Dupixent SyringeDupilumab | 16 | $48,975 |
| EliquisApixaban | 36 | $41,446 |
| JardianceEmpagliflozin | 48 | $39,916 |
| XareltoRivaroxaban | 46 | $37,505 |
| UbrelvyUbrogepant | 29 | $37,334 |
| TrulicityDulaglutide | 25 | $37,228 |
| Repatha SureclickEvolocumab | 42 | $37,059 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $32,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $831 | $181,296160 claims |
| AbbVieUbrelvy, Linzess, Vraylar, Qulipta | $1,528 | $111,42796 claims |
| NovartisEntresto | $596 | $104,858102 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $265 | $80,78191 claims |
| GSKTrelegy Ellipta, Shingrix | $97 | $76,72684 claims |
| Novo NordiskOzempic, Rybelsus | $344 | $64,09448 claims |
| PfizerEliquis, Abrysvo | $62 | $52,87172 claims |
| Johnson & JohnsonXarelto | $23 | $37,50546 claims |
| Axsome Therapeutics, Inc.Auvelity | $388 | $27,22120 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $26 | $16,51512 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $10 | $8,83614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 777 pediatrics providers in Kentucky.
Other pediatrics in Brownsville
- Sirish PalleHyden$89K
- Christian BerkhahnLouisville$85K
- Maurice AllgeierLouisville$38K
- Stanley BlockBardstown$34K
- Michael SimonNicholasville$32K
- Patricia PurcellLouisville$27K
- Daniel FinnBardstown$17K
- Lakshmi KoonapuFort Campbell$15K
- John CecilPaducah$13K
- Amber PendletonLouisville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.